Concepedia

Constantia Pantelidou

CP

Statistics

Publications

12

Citations

1.8K

H-Index

12

Active since

2010

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Brigham and Women's Hospital

Beth Israel Deaconess Medical Center

AC Camargo Hospital

Constantia Pantelidou is an author at Dana-Farber Cancer Institute specializing in oncology, molecular oncology, and medicine.

Publications per year

2010–2023

12

Publications

12

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira et al. · Cancer Discovery · 2019 · 720 citations · Full text

Medicine, Immunology, Oncology +17

A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors

Jia Zhou, Camille Gelot, Constantia Pantelidou et al. · Nature Cancer · 2021 · 337 citations · Full text

Life Sciences, Molecular Biology, Oncology +11

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

Anita K. Mehta, Emily Cheney, Christina Hartl et al. · Nature Cancer · 2020 · 259 citations · Full text

Medicine, Immunology, Oncology +16

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart et al. · Nature Cancer · 2021 · 241 citations · Full text

Medicine, Molecular Biology, Oncology +12

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells

Y. K. Stella Man, James A. Davies, Lynda Coughlan et al. · Molecular Cancer Therapeutics · 2018 · 48 citations · Full text

Medicine, Cancer Biology, Oncology +17

1–5 of 12